The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Claritev Corp is $37.50, about 39.7% above its August 6 closing price of $26.84
Drivers behind the result
Portfolio expansion - Co said a broader portfolio of solutions and entry into new sales verticals supported revenue growth
Strong bookings - Co reported notable strength in bookings, especially in the TPA market, with several large transactions
Favorable market trends - Management said favorable market trends helped drive return to top-line growth
Quarterly results beat estimates
US healthcare data and insights firm's Q2 revenue grew 6.6% yr/yr, beating analyst expectations
Q2 adjusted EBITDA rose 1.1% and beat analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance
CTEV•
